Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Optimal Duration of Dual Antiplatelet Therapy After Drug Eluting Stent (DES) Implantation.

Trial Profile

Optimal Duration of Dual Antiplatelet Therapy After Drug Eluting Stent (DES) Implantation.

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 17 Sep 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aspirin (Primary) ; Clopidogrel (Primary)
  • Indications Stent thrombosis
  • Focus Adverse reactions
  • Acronyms OPTIDUAL

Most Recent Events

  • 29 Aug 2018 Results presented at the ESC Congress 2018: Annual Congress of the European Society of Cardiology
  • 12 Sep 2015 Results published in the European Heart Journal.
  • 03 Jun 2010 Actual initiation date added to 1 Jan 2009 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top